| Effect of tyrosin kinase inhibitors on NK cell and ILC3 development and function L Damele, E Montaldo, L Moretta, C Vitale, MC Mingari Frontiers in Immunology 9, 2433, 2018 | 19 | 2018 |
| Cord blood-derived natural killer cell exploitation in immunotherapy protocols: more than a promise? L Damele, GM Spaggiari, M Parodi, MC Mingari, M Vitale, C Vitale Cancers 14 (18), 4439, 2022 | 16 | 2022 |
| Targeted therapies: friends or foes for patient’s NK cell-mediated tumor immune-surveillance? L Damele, S Ottonello, MC Mingari, G Pietra, C Vitale Cancers 12 (4), 774, 2020 | 14 | 2020 |
| EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells L Damele, A Amaro, A Serio, S Luchetti, U Pfeffer, MC Mingari, C Vitale Cancers 13 (2), 319, 2021 | 9 | 2021 |
| Murine models to study human NK cells in human solid tumors M Parodi, S Astigiano, P Carrega, G Pietra, C Vitale, L Damele, M Grottoli, ... Frontiers in Immunology 14, 1209237, 2023 | 2 | 2023 |
| Epigenetic drugs interfere with NK/ILC3 differentiation and proliferation L Damele, A Amaro, S Lucchetti, A Serio, MC Mingari, C Vitale EUROPEAN JOURNAL OF IMMUNOLOGY 51, 159-159, 2021 | | 2021 |
| EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells. Cancers 2021, 13, 319 L Damele, A Amaro, A Serio, S Luchetti, U Pfeffer, MC Mingari, C Vitale s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | | 2021 |
